Protagonist Therapeutics (PTGX) cash on hand

Cash · fiscal 2025
$567.36M

Protagonist Therapeutics (PTGX) held cash of $567.36M at the end of fiscal 2025 (December 31, 2025). That is 35.4% higher than the $418.91M of fiscal 2024. Figures as of 18 Nov 2026, 07:28 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Cash, fiscal 2025
$567.36M
Change on fiscal 2024
+35.4%
Highest on record
$567.36Mfiscal 2025
Lowest on record
$237.36Mfiscal 2022
Fiscal years on record
42022–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Protagonist Therapeutics cash on hand, in more detail

Across the 4 fiscal years on record (2022–2025), the highest was $567.36M in fiscal 2025 and the lowest $237.36M in fiscal 2022.

History · 4 fiscal years

Cash by fiscal year

Protagonist Therapeutics cash on hand, year by year

Protagonist Therapeutics (PTGX) cash on hand by fiscal year
Fiscal yearCashChangeYear ended
2025$567.36M 35.4% up
2024$418.91M 22.6% up
2023$341.62M 43.9% up
2022$237.36M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Cash is the cash, cash equivalents and short-term investments on the balance sheet at the fiscal year-end, shown for the fiscal years the market data feed covers because the older SEC record counts cash and equivalents alone.

How to read it

Cash is the cushion that pays for bad years, buybacks and acquisitions; compare it with total debt to see whether the company is a net borrower.

Cash at health care companies of similar size

Cash of Protagonist Therapeutics and comparable companies
CompanyCashFiscal year
Praxis Precision Medicines PRAX$599.33M2025
Twist Bioscience TWST$581.91M2026
Protagonist Therapeutics PTGX$567.36M2025
Krystal Biotech KRYS$827.79M2025
10x Genomics TXG$523.41M2025
HealthEquity HQY$318.93M2026

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on PTGX

Protagonist Therapeutics, figure by figure

Protagonist Therapeutics (PTGX) overview: price, valuation and scorecardAll health care companies by market value

Protagonist Therapeutics cash on hand: questions and answers

How much cash does Protagonist Therapeutics have?

Protagonist Therapeutics (PTGX) held cash of $567.36M at the end of fiscal 2025 (December 31, 2025). That is 35.4% higher than the $418.91M of fiscal 2024.

What are the highest and lowest cash figures on record for Protagonist Therapeutics?

Across the 4 fiscal years on record (2022–2025), the highest was $567.36M in fiscal 2025 and the lowest $237.36M in fiscal 2022.

How is Protagonist Therapeutics's cash calculated?

Cash is the cash, cash equivalents and short-term investments on the balance sheet at the fiscal year-end, shown for the fiscal years the market data feed covers because the older SEC record counts cash and equivalents alone.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Protagonist Therapeutics (PTGX) cash on hand”, data as of 18 November 2026. https://funkfolio.com/stock/PTGX/cash

Underlying data: the company's filings with the SEC and Yahoo Finance.